| T76691 |
Monalizumab
|
1228763-95-8
|
98%
|
Monalizumab
|
|
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NK...
|
| T14072 |
A-443654
|
552325-16-3
|
|
|
|
A-443654 is a pan-Akt inhibitor. A-443654 has equal potency against Akt1, Akt2, or Akt3 within cells (Ki=160 pM).
|
| T4310 |
Prexasertib
|
1234015-52-1
|
100%
|
|
|
Prexasertib (LY2606368) is an inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity.
|
| T13148 |
CHK-IN-1
|
1278405-51-8
|
100%
|
|
|
CHK-IN-1 is a dual inhibitor of CHK1 and CHK2 with antiproliferative activity.
|
| T10791 |
CHK1-IN-3
|
2097252-39-4
|
100%
|
|
|
CHK1-IN-3 is an inhibitor of checkpoint kinase 1 (CHK1; IC50: 0.4 nM).
|
| T71259 |
GNE-900
|
1200126-26-6
|
97.18%
|
|
|
GNE-900 is an ATP-competitive ChK1 inhibitor with selective and oral activity.GNE-900 inhibits ChKl and ChK2 with IC50 values of 0.0011 and 1.5 µM, respectively....
|
| T4327 |
Prexasertib dihydrochloride
|
1234015-54-3
|
97.5%
|
|
|
Prexasertib dihydrochloride (LY2606368) is an ATP-competitive CHK1 inhibitor (Ki: 0.9 nmol/L). in the cell-free assay, its IC50 values are 8 nM and 9 nM for CHK2...
|
| T21331 |
SAR-020106
|
1184843-57-9
|
97.78%
|
|
|
SAR-020106 is a potent, ATP-competitive, and selective CHK1 inhibitor with an IC50 of 13.3 nmol/L on the isolated human enzyme.
|
| T27407 |
GDC0575 monohydrochloride
|
1196504-54-7
|
97.85%
|
|
|
GDC0575 monohydrochloride (ARRY575) is a potent and selective inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2 nM. GDC-0575 specifically bi...
|
| T7300 |
GDC-0575
|
1196541-47-5
|
98%
|
|
|
GDC-0575 (ARRY-575) is a highly-selective oral small-molecule Chk1 inhibitor(IC50 of 1.2 nM).
|
| T10792L |
CHK1-IN-4 hydrochloride
|
|
98.02%
|
|
|
CHK1-IN-4 hydrochloride is a potent inhibitor of checkpoint kinase 1 (chk1). CHK1-IN-4 hydrochloride potently inhibits chk1 phosphorylation in the tumor cells. C...
|
| T16446 |
PD 407824
|
622864-54-4
|
98.02%
|
|
|
PD 407824 is a chemical BMP sensitiser that promotes increased cellular sensitivity to subthreshold amounts of BMP4.PD 407824 is a potent inhibitor of the checkp...
|
| T1830 |
BX795
|
702675-74-9
|
98.32%
|
|
|
BX795 is an effective and selective PDK1 inhibitor (IC50: 6 nM), and its selectivity is 140- and 1600-fold for PDK1 over PKA and PKC in cell-free assays, respect...
|
| T6028 |
PF 477736
|
952021-60-2
|
98.34%
|
|
|
PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CS...
|
| T2517 |
SCH900776
|
891494-63-6
|
98.35%
|
|
|
SCH900776 (MK-8776) is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities.
|
| T6350 |
CHIR-124
|
405168-58-3
|
98.35%
|
|
|
CHIR-124 is an effective Chk1 inhibitor (IC50: 0.3 nM). It has 2, 000-fold selectivity against Chk2, 500- to 5, 000-fold less activity against Cdc2 and CDK2/4.
|
| T15943 |
M443
|
1820684-31-8
|
98.95%
|
|
|
M443 is a potent small molecule inhibitor of MRK that inhibits radiation-induced activation of p38 and Chk2 and can be used in cancer research.
|
| T2033 |
BML-277
|
516480-79-8
|
99.09%
|
|
|
BML-277 (C 3742) is a selective checkpoint kinase 2 (Chk2) inhibitor.
|
| T6093 |
AZD-7762
|
860352-01-8
|
99.17%
|
|
|
AZD-7762, an effective and specific inhibitor of Chk1（IC50=5 nM）, is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck.
|
| T10325 |
ANI-7
|
931417-26-4
|
99.21%
|
|
|
ANI-7 is an activator of aryl hydrocarbon receptor (AhR) pathway. ANI-7 inhibits the growth of multiple cancer cells and potently and selectively inhibits the gr...
|
